Cover Image
市場調查報告書

II型糖尿病的全球市場:2016∼2020年

Global Type 2 Diabetes Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 321430
出版日期 內容資訊 英文 122 Pages
訂單完成後即時交付
價格
Back to Top
II型糖尿病的全球市場:2016∼2020年 Global Type 2 Diabetes Market 2016-2020
出版日期: 2016年03月23日 內容資訊: 英文 122 Pages
簡介

II型糖尿病是30∼75歲主要從中年到老年人中受診斷的成人疾病,佔全球糖尿病發病數量的90∼95%左右。風險因素有高血壓,老齡化,肥胖,妊娠糖尿病歷,家族病史等。全球II型糖尿病,預計2016∼2020年以年複合成長率7.28%擴大。

本報告提供全球II型糖尿病市場現狀與至2020年的成長預測,市場趨勢與課題,各地區趨勢,以及主要供應商簡介彙整。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 疾病概要

  • 簡介
  • 風險因素
  • 診斷
  • 管理
  • 流行病學
  • 經濟負擔

第6章 產品研發線

第7章 市場情況

  • 全球糖尿病藥物市場
  • 全球II型糖尿病藥物市場
  • 波特的五力分析

第8章 各類藥物市場區隔

第9章 胰島素

第10章 DPP-4抑制劑

第11章 GLP-1受體激動劑

第12章 SGLT-2抑制劑

第13章 各地區市場區隔

  • 各地區市場區隔
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第14章 推動市場的要素

第15章 促進要素的影響

第16章 市場課題

第17章 促進要素的影響與課題

第18章 市場趨勢

第19章 供應商環境

  • 競爭模式
  • 2015年的市場分析
  • Novo Nordisk
  • Sanofi
  • Merck
  • Eli Lilly
  • AstraZeneca
  • 其他值得注意的供應商

第20章 附錄

第21章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR8779

About Type 2 Diabetes

Diabetes, often referred to as diabetes mellitus, is a metabolic disease in which the patients' blood glucose levels remains high. Depending on the cause of development of diabetes, it can be divided into three types:

  • Type 1 diabetes (or insulin-dependent diabetes mellitus): In this condition, the pancreas do not produce the required amount of insulin, leading to high blood glucose levels.
  • Type 2 diabetes (non-insulin dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it, increasing the glucose levels in the body.

Gestational diabetes: This condition occurs in pregnant women without any prior history of diabetes

Type 2 diabetes, also known as adult-onset diabetes, is a result of the body's inability to produce enough insulin or insulin resistance or both. It is managed by providing symptomatic relief and improving the quality of life. Type 2 diabetes accounts for nearly 90%-95% of the total number of diabetes cases worldwide and is primarily diagnosed in the middle-aged and old age groups, i.e., between the ages of 30 and 75 years. However, it can occur even during childhood. The risks of type 2 diabetes include high blood pressure, advancing age, obesity, history of gestational diabetes, family history of diabetes, poor nutrition during pregnancy, physical inactivity, and impaired glucose tolerance.

Technavio's analysts forecast the global type 2 diabetes drugs market to grow at a CAGR of 7.28% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global type 2 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat type 2 diabetes.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Type 2 Diabetes Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca plc
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Sanofi SA

Other Prominent Vendors

  • Adocia
  • Akros Pharma
  • Amgen
  • Astellas Pharma
  • Biocon
  • Boehringer Ingelheim
  • Chipscreen Biosciences
  • ConjuChem
  • CymaBay Therapeutics
  • Daiichi Sankyo
  • DiaMedica
  • Diasome Pharmaceuticals
  • Dong-A ST
  • Elcelyx Therapeutics
  • Exsulin
  • Generex
  • Genfit
  • Hanmi
  • Hua Medicine
  • InteKrin Therapeutics
  • Ionis Pharmaceuticals
  • Janssen Pharmaceuticals
  • Japan Tobacco
  • Kadmon
  • KinDex Pharmaceuticals
  • Kissei
  • Kotobuki Pharmaceutical
  • Lexicon Pharmaceuticals
  • Ligand
  • MannKind
  • MedImmune
  • Melior Pharmaceuticals
  • Metabolic Solutions Development Company
  • Mitsubishi Tanabe Pharma
  • Novartis
  • NGM Bio
  • NuSirt Biopharma
  • Oramed
  • Peptron
  • Pfizer
  • PhaseBio
  • Poxel
  • Sanwa Kagaku Kenkyusho
  • Sirona Biochem
  • Takeda
  • Theracos
  • Theratechnologies
  • Transition Therapeutics
  • VeroScience
  • vTv Therapeutics
  • XBiotech

Market driver

  • Rising prevalence of diabetes
  • For a full, detailed list, view our report

Market challenge

  • Low diagnosis rate
  • For a full, detailed list, view our report

Market trend

  • Increase in awareness of diabetes
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Disease overview

  • Introduction
  • Risk factors
  • Diagnosis
  • Management
  • Epidemiology
  • Economic burden

PART 06: Pipeline portfolio

PART 07: Market landscape

  • Global diabetes drugs market
  • Global type 2 diabetes drugs market
  • Five forces analysis

PART 08: Market segmentation by drug class

PART 09: Insulin

  • Product portfolio
  • Global insulin market

PART 10: DPP-4 inhibitors

  • Market overview
  • Market size and forecast

PART 11: GLP-1 receptor agonists

  • Market overview
  • Market size and forecast

PART 12: SGLT-2 inhibitors

  • Market overview
  • Market size and forecast

PART 13: Geographical segmentation

  • Global type 2 diabetes drugs market by geographical segmentation 2015-2020
  • Type 2 diabetes drugs market in Americas
  • Type 2 diabetes drugs market in EMEA
  • Type 2 diabetes drugs market in APAC

PART 14: Market drivers

  • Rising prevalence of diabetes
  • Rise in obesity rates
  • Growing older population
  • Unmet medical needs
  • Stringent regulatory guidelines for biosimilar drugs

PART 15: Impact of drivers

PART 16: Market challenges

  • Low diagnosis rate
  • Rising concerns in scientific community
  • Gaps in national-level diabetes management plans
  • Poor storage conditions and distribution policies for insulin
  • Fierce market competition

PART 17: Impact of drivers and challenges

PART 18: Market trends

  • Increase in awareness of diabetes
  • Increase in academia-industry collaboration
  • Rising price of diabetes drugs
  • Increase in R&D

PART 19: Vendor landscape

  • Competitive scenario
  • Market analysis 2015
  • Novo Nordisk
  • Sanofi
  • Merck
  • Eli Lilly
  • AstraZeneca
  • Other prominent vendors

PART 20: Appendix0

  • List of abbreviations

PART 21: Explore Technavio1

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for type 2 diabetes drugs
  • Exhibit 03: Line of therapy for type 2 diabetes
  • Exhibit 04: Pipeline portfolio: Global type 2 diabetes drugs market
  • Exhibit 05: Global diabetes drugs market by prevalence based on type of disease 2015
  • Exhibit 06: Top selling diabetes drugs based on sales 2014 ($ billions)
  • Exhibit 07: Market share of global diabetes drugs in global pharmaceutical drugs market 2015
  • Exhibit 08: Global diabetes drugs market 2015-2020 ($ billions)
  • Exhibit 09: Market share analysis of vendors in global diabetes drugs market
  • Exhibit 10: Global type 2 diabetes drugs market 2015-2020 ($ billions)
  • Exhibit 11: Five forces analysis
  • Exhibit 12: Segmentation of global type 2 diabetes drugs market by drug class
  • Exhibit 13: Segmentation of global type 2 diabetes drugs market by drug class 2015
  • Exhibit 14: Comparison of different classes of type 2 diabetes drugs
  • Exhibit 15: Global human insulin market 2015-2020 ($ billions)
  • Exhibit 16: Global insulin market revenues by type of diabetes 2015
  • Exhibit 17: Segmentation of global insulin market based by drug class 2015
  • Exhibit 18: Segmentation of global insulin market by geography 2015
  • Exhibit 19: DPP-4 inhibitor drugs approved in market
  • Exhibit 20: Global DPP-4 inhibitors drugs market for type 2 diabetes 2015-2020 ($ billions)
  • Exhibit 21: GLP-1 receptor agonists approved in market
  • Exhibit 22: Global GLP-1 receptor agonists drugs market for type 2 diabetes 2015-2020 ($ billions)
  • Exhibit 23: Segmentation of global GLP-1 receptor agonists drugs market for type 2 diabetes by geography 2015
  • Exhibit 24: Approved SGLT-2 inhibitor drugs
  • Exhibit 25: Global SGLT-2 inhibitors market for type 2 diabetes 2015-2020 ($ billions)
  • Exhibit 26: Segmentation of global type 2 diabetes drugs market by geography 2015
  • Exhibit 27: Global type 2 diabetes drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 28: Percentage share of global type 2 diabetes drugs market by geography 2015-2020
  • Exhibit 29: Type 2 diabetes drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 30: Segmentation of type 2 diabetes drugs market in Americas by country 2015
  • Exhibit 31: Type 2 diabetes drugs market in US 2015-2020 ($ billions)
  • Exhibit 32: Type 2 diabetes drugs market in Brazil 2015-2020 ($ billions)
  • Exhibit 33: Type 2 diabetes drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 34: Type 2 diabetes drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 35: Segmentation of type 2 diabetes drugs market in APAC by country 2015
  • Exhibit 36: Global type 2 diabetes drugs market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 37: Impact of drivers
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: YOY revenues from sales of top seven products in global type 2 diabetes drugs market 2012-2014 ($ billions)
  • Exhibit 40: Novo Nordisk: Business segmentation by revenue 2015
  • Exhibit 41: Novo Nordisk: R&D expenditure 2015
  • Exhibit 42: Novo Nordisk: Key product offerings in global type 2 diabetes drugs market
  • Exhibit 43: Novo Nordisk: YoY revenue and growth rate generated from net product sales of human insulins 2012-2015 ($ billions)
  • Exhibit 44: Novo Nordisk: YoY revenue and growth rate generated from net product sales of Levemir 2012-2015 ($ billions)
  • Exhibit 45: Novo Nordisk: YoY revenue and growth rate of NovoRapid/NovoLog 2012-2015 ($ billions)
  • Exhibit 46: Novo Nordisk: Revenues of NovoRapid/NovoLog by geography 2015
  • Exhibit 47: Novo Nordisk: YoY revenue and growth rate of NovoMix/NovoLog Mix 2012-2015 ($ billions)
  • Exhibit 48: Novo Nordisk: Revenues of NovoMix/NovoLog Mix by geography 2015
  • Exhibit 49: Novo Nordisk: YOY revenue and growth rate generated from net product sales of new-generation insulins 2013-2015 ($ millions)
  • Exhibit 50: Novo Nordisk: YoY revenue and growth rate of Victoza 2012-2015 ($ billions)
  • Exhibit 51: Novo Nordisk: YoY revenue and growth rate of Victoza in US 2013-2015 ($ billions)
  • Exhibit 52: Novo Nordisk: YoY revenue and growth rate of Victoza in Europe 2013-2015 ($ billions)
  • Exhibit 53: Novo Nordisk: YoY revenue and growth rate of Novonorm, Prandin, and Prandimet 2012-2014 ($ billions)
  • Exhibit 54: Novo Nordisk: Key takeaways
  • Exhibit 55: Sanofi: Business segmentation by revenue 2015
  • Exhibit 56: Sanofi: Key product offerings in global type 2 diabetes drugs market
  • Exhibit 57: Sanofi: YoY revenue and growth rate of Lantus 2012-2015 ($ billions)
  • Exhibit 58: Sanofi: Geographical segmentation of Lantus by revenue 2015
  • Exhibit 59: Sanofi: YoY revenue and growth rate of Amaryl 2012-2015 ($ millions)
  • Exhibit 60: Sanofi: Geographical segmentation of Amaryl by revenue 2015
  • Exhibit 61: Sanofi: YoY revenue and growth rate of Apidra 2012-2015 ($ millions)
  • Exhibit 62: Sanofi: Geographical segmentation of Toujeo by revenue 2015
  • Exhibit 63: Sanofi: YoY revenue and growth rate of Insuman 2012-2015 ($ millions)
  • Exhibit 64: Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions)
  • Exhibit 65: Sanofi: Key takeaways
  • Exhibit 66: Merck: Business segmentation by revenue 2015
  • Exhibit 67: Merck: Diabetes segmentation by revenue 2015
  • Exhibit 68: Merck: Key product offerings in global type 2 diabetes drugs market
  • Exhibit 69: Merck: YoY revenue and growth rate of Janumet 2012-2015 ($ billions)
  • Exhibit 70: Merck: YoY revenue and growth rate of Januvia from 2012-2015 ($ billions)
  • Exhibit 71: Merck: Key takeaways0
  • Exhibit 72: Eli Lilly: Key product offerings in global type 2 diabetes drugs market1
  • Exhibit 73: Eli Lilly: YoY revenue and growth rate of Humalog 2012-2015 ($ billions)1
  • Exhibit 74: Eli Lilly: YoY revenue and growth rate of Humalog in US 2013-2015 ($ billions)2
  • Exhibit 75: Eli Lilly: YoY revenue and growth rate of Humalog in ROW 2013-2015 ($ billions)2
  • Exhibit 76: Eli Lilly: YoY revenue and growth rate of Humulin 2012-2015 ($ billions)3
  • Exhibit 77: Eli Lilly: YoY revenue and growth rate of Humulin in US 2013-2015 ($ millions)3
  • Exhibit 78: Eli Lilly: YoY revenue and growth rate of Humulin in ROW 2013-2015 ($ millions)3
  • Exhibit 79: Eli Lilly: YoY revenue and growth rate of Tradjenta 2012-2015 ($ millions)4
  • Exhibit 80: Eli Lilly: YoY revenue of Trulicity 2014-2015 ($ millions)5
  • Exhibit 81: Eli Lilly: Trulicity geographical segmentation by revenue 20155
  • Exhibit 82: Eli Lilly: Key takeaways7
  • Exhibit 83: AstraZeneca: Key product offerings in global type 2 diabetes drugs market9
  • Exhibit 84: AstraZeneca: Farxiga/Forxiga geographical segmentation by revenues 20159
  • Exhibit 85: AstraZeneca: YoY revenues and growth rate of Byetta 2012-2015 ($ millions)0
  • Exhibit 86: AstraZeneca: YoY revenues and growth rate of Byetta in US ($ millions)0
  • Exhibit 87: AstraZeneca: YoY revenues and growth rate of Bydureon 2012-2015 ($ millions)1
  • Exhibit 88: AstraZeneca: YoY revenues and growth rate of Bydureon in US ($ millions)1
  • Exhibit 89: AstraZeneca: YoY revenues and growth rate of Onglyza 2012-2015 ($ millions)2
  • Exhibit 90: AstraZeneca: YoY revenues and growth rate of Onglyza/Kombiglyze XR/Komboglyze in US ($ millions)2
  • Exhibit 91: AstraZeneca: Key takeaways
Back to Top